Staphylococcal immunotherapeutics via donor selection and donor stimulation
A method and composition for the passive immunization of patients infected with or susceptible to infection from Staphylococcus bacteria such as S. aureus and S. epidermidis infection is provided that includes the selection or preparation of a donor plasma pool with high antibody titers to carefully selected Staphylococcus adhesins or MSCRAMMs, or fragments or components thereof, or sequences with substantial homology thereto. The donor plasma pool can be prepared by combining individual blood or blood component samples which have higher than normal titers of antibodies to one or more of the selected adhesins or other proteins that bind to extracellular matrix proteins, or by administering carefully selected proteins or peptides to a host to induce the expression of desired antibodies, and subsequently recovering the enhanced high titer serum or plasma pool from the treated host. In either case, the donor plasma pool is preferably purified and concentrated prior to intravenous introduction into the patient, and the present invention is advantageous in that a patient can be immunized against a wide variety of potentially dangerous staphylococcal infections. Kits for identifying potential donor with high titers of the selected adhesins are also provided. The present invention thus provides methods and compositions which can be highly effective against infections associated with Staphylococcus bacteria.
1. A method of obtaining a purified human donor immunoglobulin composition comprising an antibody titer to an S. aureus serine-aspartate repeat (Sdr) protein in combination with an antibody titer to an S. epidermidis serine-asparate repeat (Sdr) protein wherein both antibody titers are higher than that found in pooled intravenous immunoglobulin obtained from unselected human donors, said method comprising obtaining blood or plasma samples from human donors, screening said samples so as to select those samples having an antibody titer to an S. aureus Sdr protein and an antibody titer an S. epidermidis Sdr protein that are both in an amount that is higher than that found in pooled intravenous immunoglobulin obtained from unselected donors, recovering blood or plasma from the selected high-titer donors, and treating the donor blood plasma to obtain immunoglobulin in a purified state having an antibody titer to an S. aureus Sdr protein and an antibody titer to an S. epidermidis Sdr protein that are both in an amount which is higher than that found in pooled intravenous immunoglobulin obtained from unselected human donors.
2. The method of claim 1 wherein the S. aureus Sdr protein is selected from the group consisting of clumping factor A (ClfA), clumping factor B (ClfB), SdrC, SdrD, and SdrE.
3. The method of claim 1 wherein the S. epidermidis Sdr protein is selected from the group consisting of SdrF, SdrG and SdrH.
4. The method of claim 1 wherein the resulting composition has an antibody titer to an S. aureus Sdr protein in an amount that is 2-fold or greater than that found in pooled intravenous immunoglobulin obtain from unselected donors.
5. The method of claim 1 wherein the resulting composition has a total antibody titer to an S. aureus Sdr protein that is greater than 0.2 Units/mg/lgG.
6. The method according to claim 1 wherein donors having a high titer to a staphylococcal Sdr protein are determined by identifying those samples having a high titer of antibodies to the A domain of the staphylococcal Sdr protein.
7. A method of obtaining a purified human donor immunoglobulin composition comprising an antibody titer to an S. aureus serine-aspartate repeat (Sdr) protein in combination with an antibody titer to an S. epidermidis serine-asparate repeat (Sdr) protein wherein both antibody titers are higher than that found in pooled intravenous immunoglobulin obtained from unselected human donors, said method comprising administering an S. aureus Sdr protein to a human host donor in an amount sufficient to induce an antibody titer to the S. aureus Sdr protein that is higher that found in pooled intravenous immunoglobulin obtained from unselected donors, and administering an S. epidermidis Sdr protein to a human host donor in an amount sufficient to induce an antibody titer to the S. epidermidis Sdr protein that is higher than that found in pooled intravenous immunoglobulin obtained from unselected donors, recovering blood or plasma samples from the induced donors, and treating the donor blood or plasma to obtain immunoglobulin in a purified state having antibody titer to an S. aureus Sdr protein and an antibody titer to an S. epidermidis Sdr protein that are both in an amount which is higher than that found in pooled intravenous immunoglobulin obtained from unselected human donors.
8. The method of claim 7 wherein the S. aureus Sdr protein is selected from the group consisting of clumping factor A (ClfA), clumping factor B (ClfB), SdrC, SdrD, and SdrE.
9. The method of claim 7 wherein the S. epidermidis Sdr protein is selected from the group consisting of SdrF, SdrG and SdrH.
10. The method of claim 7 wherein the resulting composition has an antibody titer to an S. aureus Sdr protein in an amount that is 2-fold or greater than that found in pooled intravenous immunoglobulin obtain from unselected donors.
11. The method of claim 7 wherein the resulting composition has a total antibody titer to an S. aureus Sdr protein that is greater than 0.2 Units/mg/lgG.
12. The method of claim 7 wherein the Sdr protein administered to a human host donor is the A domain of the staphylococcal Sdr protein.